AI and Cancer Research ── Lung ── 2026-09-30


Lung cancer: treatment, trials and AI
- Abstract
Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I 3 LUNG ( NCT05537922 ) is currently the largest international, real-world, multimodal, artificial intelligence (AI)-based study, enrolling 2,396 patients. We integrated real-world clinical and blood (CB) data, computed tomography (CT) images, digital pathology (DP), and genomics into machine learning early fusion (MLEF) and deep learning intermediate fusion (DLIF) models. Machine learning (ML) and deep learning (DL) CB-only models achieved consistent performance across outcomes with area under the curve (AUC) up to 0.77 in the test (TEST) set. Performance drop in external validation (EXVAL) likely reflects population differences (AUC range: 0.55-0.72). AI models significantly surpassed PD-L1, Eastern Cooperative Oncology Group performance status (ECOG PS), neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and Lung Immune Prognostic Index (LIPI) score in the independent TEST set. The clinical usability study showed that lung expert and nonexpert physicians improved their prediction with the explainable AI (XAI) ML CB-only based tool. Although multimodal integration with MLEF (CB+CT+DP) was associated with higher performance, its incremental benefit remains uncertain, not translated in TEST and EXVAL. The I 3 LUNG project is a pioneering framework showing the clinical usefulness of AI tools. A prospective validation of the decision support system (both CB and multimodal) is currently undergoing in more than 2,000 patients.
Reference: Prelaj A, Miskovic V, Sacco M, Ferrarin A, Licciardello CM, Provenzano L, et al. Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC. Nat Med. 2026 Sep 13;32(9):3235-47. doi:10.1038/s41591-026-04488-2. PMID: 42733093; PMCID: PMC13577906.Checked: Full text checked - Abstract
Multi-task DL for predicting EGFR mutation status Epidermal growth factor receptor (EGFR) mutation status is a critical biomarker in the management of non-small cell lung cancer (NSCLC), playing an essential role in selecting patients for EGFR-targeted treatment. With advancements in deep learning (DL), there is a growing interest in developing non-invasive methods for predicting EGFR mutation status. In this study, we present a multi-task deep learning (MTDL) model that utilizes CT images to predict EGFR mutation status (ChiCTR2400083082 in the WHO International Clinical Trials Registry). Our MTDL model achieved promising performance in accurately predicting EGFR mutation status. Additionally, the MTDL score was significantly associated with survival in patients receiving EGFR-targeted treatment, as well as relevant gene expression patterns and tumor microenvironment. These findings suggest that our method has the potential to serve as an accurate and non-invasive biomarker for predicting EGFR mutation status, thereby facilitating personalized treatment decisions for NSCLC patients.
Reference: Song Q, Li X, Song B, Ye W, Zhang T, Hu X, et al. Multi-task deep learning model for predicting EGFR mutation status in NSCLC. NPJ Digit Med. 2026 Jul 20 [Epub ahead of print]. doi:10.1038/s41746-026-03007-4. PMID: 42477500.Checked: Abstract only - Abstract
Accurate prediction of epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma (LUAD) with brain metastases (BMs) is crucial for guiding targeted therapy. However, noninvasive and biologically interpretable tools remain limited. In this multicenter radiogenomic study, we analyzed a total of 1303 BMs from 421 LUAD patients across three institutions. 3435 radiomic features were extracted from T1, T2, and contrast-enhanced T1 sequences. A four-task classification framework was developed to predict EGFR mutation status (EGFR+, 19Del, L858R, or sensitizing mutation) using an adaptive LightGBM-based modeling pipeline. The models achieved excellent performance in the internal cohort (AUCs up to 0.95) and were further validated in 94 lesions with pathologically confirmed EGFR status, reaching an accuracy of 83.0%, sensitivity of 84.7%, and specificity of 80.0%. SHAP and LIME analyses revealed that shape-based radiomic features, particularly original_shape_sphericity, were the most important predictors of EGFR mutational subtypes. Then, we conducted transcriptomic analysis on 38 matched surgical specimens. Radiogenomic correlation revealed that sphericity negatively correlated with RNF125 and SLC37A2. Downstream enrichment analysis identified EGFR-associated features linked to DNA replication, sister chromatid segregation, and ERBB signaling. The study demonstrates that radiogenomic modeling, grounded in interpretable biology, holds promise as a non-invasive, clinical strategy for precision stratification of LUAD BMs.
Reference: Deng F, Chu X, Shi W, Xiao G, Tanzhu G, Niu L, et al. Radiogenomic modeling of EGFR mutation status in brain metastases from lung adenocarcinoma: a multicenter study with biological interpretability. NPJ Digit Med. 2026 Jul 6 [Epub ahead of print]. doi:10.1038/s41746-026-02931-9. PMID: 42410125.Checked: Abstract only